ReviewSensors (Basel, Switzerland)2024
Non-Athletic Cohorts Enrolled in Longitudinal Whole-Body Electromyostimulation Trials-An Evidence Map.
Review in Sensors (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Whole-Body Electromyostimulation on Metabolic Syndrome in Adults at Moderate-to-High Cardiometabolic Risk-A Systematic Review and Meta-Analysis.Sensors (Basel, Switzerland) · 2024Pooled it
- Effects of Longitudinal Whole-Body Electromyostimulation on Maximum Strength and Power in Sportspeople and Athletes-A Systematic Review and Meta-Analysis.Muscles (Basel, Switzerland) · 2026Review
- Effects of Whole-Body Electromyostimulation on Jumping, Sprinting and Agility Performance in Sportspeople and Athletes: Systematic Review and Meta-Analysis.Journal of functional morphology and kinesiology · 2026Review
- Electromyostimulation-Induced Rhabdomyolysis: A Case Report and Comprehensive Literature Review.Cureus · 2025Article
- Outcomes Addressed by Whole-Body Electromyostimulation Trials in Sportspeople and Athletes-An Evidence Map Summarizing and Categorizing Current Findings.Sports (Basel, Switzerland) · 2025Review
- Sarcopenia prevention in older adults: Effectiveness and limitations of non-pharmacological interventions.Osteoporosis and sarcopenia · 2025Review
- The effect of whole-body electromyostimulation on visceral adipose tissue volume in overweight-to-obese adults with knee osteoarthritis: A randomized controlled study.Frontiers in physiology · 2025Article
- Enhancing Physical and Cognitive Efficiency in Elderly Individuals at Risk for Dementia Using Whole-Body Electrostimulation: A Randomized Controlled Trial.Journal of functional morphology and kinesiology · 2024Article
- Effects of whole-body electromyostimulation with different impulse intensity on blood pressure changes in hyper- and normotensive overweight people. A pilot study.Frontiers in physiology · 2024Article
- Commentary: Revised contraindications for the use of non-medical WB-electromyostimulation. Evidence-based German consensus recommendations.Frontiers in sports and active living · 2024Article
- Response: Commentary: Revised contraindications for the use of non-medical WB-electromyostimulation. Evidence-based German consensus recommendations".Frontiers in sports and active living · 2024Article
- Revised contraindications for the use of non-medical WB-electromyostimulation. Evidence-based German consensus recommendations.Frontiers in sports and active living · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whole-body electromyostimulation (WB-EMS) can be considered as a time-efficient, joint-friendly, and highly customizable training technology that attracts a wide range of users. The present evidence map aims to provide an overview of different non-athletic cohorts addressed in WB-EMS research. Based on a comprehensive systematic search according to PRISMA, eighty-six eligible longitudinal trials were identified that correspond with our eligibility criteria. In summary, WB-EMS research sufficiently covers all adult age categories in males and females. Most cohorts addressed (58%) were predominately or exclusively overweight/obese, and in about 60% of them, diseases or conditions were inclusion criteria for the trials. Cohorts specifically enrolled in WB-EMS trials suffer from cancer/neoplasm (n = 7), obesity (n = 6), diabetes mellitus (n = 5), metabolic syndrome (n = 2), nervous system diseases (n = 2), chronic heart failure (n = 4), stroke (n = 1), peripheral arterial diseases (n = 2), knee arthrosis (n = 1), sarcopenia (n = 3), chronic unspecific low back pain (n = 4), and osteopenia (n = 3). Chronic kidney disease was an eligibility criterion in five WB-EMS trials. Finally, three studies included only critically ill patients, and two further studies considered frailty as an inclusion criterion. Of importance, no adverse effects of the WB-EMS intervention were reported. In summary, the evidence gaps in WB-EMS research were particular evident for cohorts with diseases of the nervous and cerebrovascular system.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.